{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:30Z","timestamp":1793987490564,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ijantimicag.2024.107134","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T17:15:20Z","timestamp":1709658920000},"page":"107134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-9995","authenticated-orcid":false,"given":"Marianna","family":"Meschiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Faltoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaniko","family":"Kaleci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Burastero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4512-4835","authenticated-orcid":false,"given":"Gabriele","family":"Melegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Venturelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bertellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Girardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107134_bib0001","unstructured":"Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science n.d. Available at: https:\/\/www.science.org\/doi\/10.1126\/science.166.3901.122 [accessed 27 April 2023]."},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0003","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jac\/35.1.228","article-title":"Antibacterial spectrum of fosfomycin trometamol","volume":"35","author":"Barry","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jac\/dkp230","article-title":"High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection","volume":"64","author":"Schintler","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0006","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","article-title":"Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review","volume":"20","author":"Tsegka","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0008","first-page":"30","article-title":"The role of fosfomycin in osteoarticular infection","volume":"32","author":"Morata","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0009","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0010","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dky406","article-title":"Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem","volume":"74","author":"Perdig\u00e3o Neto","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01682-18","article-title":"The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0013","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/1120009X.2020.1745501","article-title":"In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and\/or NDM-producing Klebsiella pneumoniae","volume":"32","author":"Erturk Sengel","year":"2020","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0014","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0015","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkaa095","article-title":"In vitro synergy of ceftolozane\/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa","volume":"75","author":"Cuba","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0016","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2\/3 randomized trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0018","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0019","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/archdischild-2021-322483","article-title":"Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload","volume":"107","author":"Obiero","year":"2022","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0020","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.jinf.2021.08.004","article-title":"Successful outcome after treatment with a combination of meropenem and fosfomycin for VIM-1 and CTX-M-15 producing Klebsiella pneumoniae bloodstream infection","volume":"83","author":"P\u00e9rez-Palacios","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii: a prospective, observational study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0024","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/jac\/dkab134","article-title":"Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study","volume":"76","author":"Babich","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0025","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ijantimicag.2018.09.008","article-title":"Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia","volume":"52","author":"Khawcharoenporn","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106512","article-title":"Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis","volume":"59","author":"Onorato","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0028","first-page":"31","article-title":"Infezioni in Medicina","year":"2023","journal-title":"Infez Med"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0031","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jgar.2023.03.010","article-title":"Real-life experience with IV fosfomycin in Canada: results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry","volume":"33","author":"Zhanel","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0032","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/cid\/ciad100","article-title":"Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram-negative bacilli: results from a nationwide study in Italy (ALARICO Network)","volume":"76","author":"Falcone","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0033","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101880","article-title":"Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"58","author":"Daghmouri","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050105","article-title":"Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial","volume":"11","author":"Mo","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0036","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00134-022-06690-5","article-title":"Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial","volume":"48","author":"Bougl\u00e9","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01446-21","article-title":"Differences in fosfomycin resistance mechanisms between Pseudomonas aeruginosa and Enterobacterales","volume":"66","author":"Zheng","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0038","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/antibiotics11121739","volume":"11","author":"Gatti","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2016.06.017","article-title":"Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic\/pharmacodynamic (PK\/PD) simulation","volume":"50","author":"Asuphon","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0040","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0041","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02549-18","article-title":"Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against Gram-negative bacterial strains by using time-kill curves","volume":"63","author":"Flamm","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0042","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/jac\/dkac241","article-title":"Activity of cefiderocol, imipenem\/relebactam, cefepime\/taniborbactam and cefepime\/zidebactam against ceftolozane\/tazobactam- and ceftazidime\/avibactam-resistant Pseudomonas aeruginosa","volume":"77","author":"Lasarte-Monterrubio","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107134_bib0043","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"J Antimicrob Chemother Antimicrob Resist"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T06:28:12Z","timestamp":1714285692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0924857924000529"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107134","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107134"}}